<DOC>
	<DOCNO>NCT00794365</DOCNO>
	<brief_summary>The primary objective Post-Marketing Study monitor safety novel smoke cessation drug Varenicline ( Champix™ ) 0.5 mg 1 mg tablet use clinical practice 12 week among Filipino smoker . The secondary objective evaluate effectiveness Varenicline ( Champix™ ) aid smoke cessation base 7-day point prevalence smoking cessation</brief_summary>
	<brief_title>Post Marketing Surveillance Study Champix Smoking Cessation Filipino Patients</brief_title>
	<detailed_description>The study enroll smoke patient .</detailed_description>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Smoking adult age ≥ 18 year intend quit tobacco use prescribed Varenicline ( Champix™ ) Physicians prescribe Varenicline ( Champix™ ) first time . Subjects varenicline ( Champix™ ) may take manner accord approve local product document . Pregnant lactate woman , woman childbearing potential use acceptable method contraception Subjects know hypersensitivity varenicline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Smoking ; smoke cessation ; Philippines ; Varenicline</keyword>
</DOC>